• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study.

作者信息

Bagit Ahmed, Maliyar Khalad, Mansour Mark, Georgakopoulos Jorge R, Rankin Brian, Lytvyn Yuliya, Zaaroura Hiba, Park Ye-Jean, Wang Emilie, Mufti Asfandyar, Torres Tiago, Le Ana M, Vender Ronald, Prajapati Vimal H, Yeung Jensen

机构信息

Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

出版信息

J Am Acad Dermatol. 2024 Sep;91(3):513-515. doi: 10.1016/j.jaad.2024.03.048. Epub 2024 Apr 25.

DOI:10.1016/j.jaad.2024.03.048
PMID:
38677338
Abstract
摘要

相似文献

1
Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study.司库奇尤单抗在成年斑块状银屑病患者中的真实世界有效性和安全性：一项为期1年的国际多中心回顾性队列研究。
J Am Acad Dermatol. 2024 Sep;91(3):513-515. doi: 10.1016/j.jaad.2024.03.048. Epub 2024 Apr 25.
2
Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.肥胖的中度至重度斑块状银屑病患者使用司库奇尤单抗的104周真实世界回顾性研究。
Arch Dermatol Res. 2024 Oct 9;316(9):667. doi: 10.1007/s00403-024-03419-w.
3
Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.司库奇尤单抗治疗加拿大两家实际临床皮肤科诊所中重度斑块状银屑病的疗效与安全性：一项多中心回顾性研究
J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e32-e34. doi: 10.1111/jdv.14468. Epub 2017 Aug 2.
4
Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study.伴有和不伴有心血管代谢合并症的中重度银屑病患者使用 risankizumab 的长期疗效和安全性：一项单中心回顾性研究。
J Dermatolog Treat. 2024 Dec;35(1):2425029. doi: 10.1080/09546634.2024.2425029. Epub 2024 Nov 7.
5
Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.瑞莎珠单抗与优特克单抗治疗中度至重度斑块状银屑病的对比
Dermatol Ther. 2017 Sep;30(5). doi: 10.1111/dth.12507. Epub 2017 May 16.
6
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.瑞莎珠单抗与甲氨蝶呤治疗中重度斑块状银屑病患者的疗效和安全性：来自巴西一项随机、双盲、3期研究IMMbrace并设有开放标签延长期的结果
An Bras Dermatol. 2025 Mar-Apr;100(2):260-271. doi: 10.1016/j.abd.2024.08.002. Epub 2024 Dec 7.
7
Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study).司库奇尤单抗治疗极重度斑块状银屑病的有效性和安全性：一项真实世界回顾性研究（VESPA研究）
J Dermatolog Treat. 2024 Dec;35(1):2358150. doi: 10.1080/09546634.2024.2358150. Epub 2024 May 22.
8
Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.老年银屑病患者的抗白细胞介素-23 治疗：真实世界中 Guselkumab、Risankizumab 和 Tildrakizumab 的应用。
Clin Exp Dermatol. 2022 Mar;47(3):561-567. doi: 10.1111/ced.14979. Epub 2021 Nov 17.
9
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.利纳西珠单抗与乌司奴单抗治疗中重度斑块状银屑病的疗效比较。
N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017.
10
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.在中重度斑块型银屑病中的疗效和安全性（UltIMMa-1 和 UltIMMa-2）：两项双盲、随机、安慰剂对照和乌司奴单抗对照的 3 期临床试验结果。
Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.